The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
High Oct4 expression: implications in the pathogenesis of neuroblastic tumours
Open accessAbstract
BACKGROUND: Neuroblastic tumours (NBTs) are paediatric solid tumours derived from embryonic neural crest cells which harbour their own cancer stem cells (CSC). There is evidence indicating that CSC may be responsible for tumour progression, chemotherapy resistance and recurrence in NBTs. Oct4 is a transcription factor which plays a key role in mammal embryonic development and stem cell fate regulation. The aim of the study is to elucidate the clinical significance of Oct4 in NBTs. METHODS: cell percentage. Survival analysis was carried out with Kaplan-Meier curves and log-rank test. Additionally, a multivariate Cox regression analysis with the stepwise backwards (Wald) method was undertaken to calculate the impact of Oct4 expression level on survival. RESULTS: We found that tumours with a high proportion of cells expressing Oct4 correlated statistically with undifferentiated and poorly differentiated neuroblastoma / nodular ganglioneuroblastoma, and that Oct4 expression was not present in ganglioneuroma (p < 0.05). Statistical analysis also indicated a relationship between high Oct4 expression levels, high-risk patients according to the International Neuroblastoma Risk Group pre-treatment classification parameters, larger blood vessels and low survival rates. CONCLUSIONS: These results suggest that the Oct4 gene may regulate NBT pathogenic differentiation pathways, and should thus be considered as a target for knockdown when developing novel therapies for high-risk NBT patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomechanics and biophysics of cancer cells☆
SURESH, S. (2007) · Acta Biomaterialia · doi:10.1016/j.actbio.2007.04.002 · Cited by 1,284
Head and neck survivorship care in the times of the SARS‐CoV‐2 pandemic
Huang, V. W., Imam, S. A., & Nguyen, S. A. (2020) · Head & Neck · doi:10.1002/hed.26235 · Cited by 9
Research works printed but not linked: 49
- Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. · DOI · Paper page
- Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36(4):277–85. · DOI · Paper page
- Vandesompele J, Van Roy N, Van Gele M, et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer. 1998;23(2):141–52. · doi:10.1002/(sici)1098-2264(199810)23:2<141::aid-gcc7>3.0.co;2-2
- Ambros IM, Speleman F, Ambros PF. Nervous system: peripheral neuroblastic tumours (neuroblastoma, ganglioneuroblastoma, ganglioneuroma). Atlas Genet Cytogenet Oncol Haematol. 2009;13(1):84–9.
- Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–16. · DOI · Paper page
- Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the international neuroblastoma risk group (INRG) biology committee. Br J Cancer. 2009;100(9):1471–82. · DOI · Paper page
- Cohn SL, Pearson AD, London WB, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27(2):289–97. · DOI · Paper page
- Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in paediatric oncology. Nat Rev Clin Oncol. 2011;8(9):540–9. · DOI · Paper page
- Kim RJ, Nam JS. OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab Anim Res. 2011;27(2):147–52. · DOI
- Kumar SM, Liu S, Lu H, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene. 2012;31(47):4898–911. · DOI · Paper page
- Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene. 2001;20(56):8085–91. · DOI · Paper page
- Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 1998;95(3):379–91. · DOI · Paper page
- Pan GJ, Chang ZY, Schöler HR, Duanqing PEI. Stem cell pluripotency and transcription factor Oct4. Cell Res. 2002;12(5–6):321–9. · DOI · Paper page
- Simandi Z, Horvath A, Wright LC, et al. OCT4 acts as an integrator of pluripotency and signal-induced differentiation. Mol Cell. 2016;63(4):647–61. · DOI
- Renshaw AA, Gould EW. OCT4 staining increases the detection of lymphatic/vascular invasion in pure seminoma of the testis obscured by prominent lymphohistiocytic inflammation. Pathology. 2016;48(3):210–3. · doi:10.1016/j.pathol.2016.02.009
- Emerson RE, Cheng L. Premalignancy of the testis and paratestis. Pathology. 2013;45(3):264–72. · doi:10.1097/pat.0b013e32835f3e1a
- Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer. 2007;120(7):1598–602. · doi:10.1002/ijc.22508
- Chen Z, Xu WR, Qian H, et al. Oct4, a novel marker for human gastric cancer. J Surg Oncology. 2009;99(7):414–9. · DOI
- Cheng L, Thomas A, Roth LM, Zheng W, Michael H, Karim FWA. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004;28(10):1341–6. · DOI
- Liu T, Sun B, Zhao X, et al. OCT4 expression and vasculogenic mimicry formation positively correlate with poor prognosis in human breast cancer. Int J Mol Sci. 2014;15(11):19634–49. · doi:10.3390/ijms151119634
- Villodre ES, Kipper FC, Pereira MB, Lenz G. Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis. Cancer Treat Rev. 2016;51:1–9. · DOI
- Rodini CO, Suzuki DE, Saba-Silva N, et al. Expression analysis of stem cell-related genes reveal OCT4 as a predictor of poor clinical outcome in medulloblastoma. J Neuro-Oncol. 2012;106(1):71–9. · DOI
- Yang L, Zheng J, Xu T, Xiao X. Downregulation of OCT4 promotes differentiation and inhibits growth of BE (2)-C human neuroblastoma I-type cells. Oncol Rep. 2013;29(6):2191–6. · DOI
- Melone MA, Giulano M, Squillaro T, et al. Genes involved in regulation of stem cell properties: studies on their expression in a small cohort of neuroblastoma patients. Cancer Biol Ther. 2009;8(13):1300–6. · DOI
- Newton TC, Wolcott K, Roberts SS. Comparison of the side populations in pre-treatment and postrelapse neuroblastoma cell lines. Transl Oncol. 2010;3(4):246–51. · DOI
- Pezzolo A, Parodi F, Marimpietri D, et al. Oct-4+/tenascin C+ neuroblastoma cells serve as progenitors of tumour-derived endothelial cells. Cell Res. 2011;21(10):1470–86. · DOI
- Monajemzadeh M, Soleimani V, Vasei M, Koochakzadeh L, Karbakhsh M. Expression and prognostic significance of Oct4 and Nanog in neuroblastoma. APMIS. 2014;122(9):734–41. · doi:10.1111/apm.12207
- Yang S, Zheng J, Ma Y, et al. Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by chemotherapy. Oncol Rep. 2012;28(1):186–92.
- Kaneko Y, Suenaga Y, Islam SM, et al. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas. Cancer Sci. 2015;106(7):840–7. · DOI
- Hamilton PW, Bankhead P, Wang Y, et al. Digital pathology and image analysis in tissue biomarker research. Methods. 2014;70(1):59–73. · DOI · Paper page
- Laurinavicius A, Laurinaviciene A, Dasevicius D, et al. Digital image analysis in pathology: benefits and obligation. Anal Cell Pathol (Amst). 2012;35(2):75–8. · doi:10.1155/2012/243416
- Rizzardi AE, Johnson AT, Vogel RI, et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol. 2012;7(1):42. · DOI · Paper page
- Tadeo I, Berbegall AP, Castel V, et al. Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort. Br J Cancer. 2016;115(4):480–9. · DOI
- Soheili S, Asadi M, Farsinejad A. Distinctive expression pattern of OCT4 variants in different types of breast cancer. Cancer Biomarkers. 2017;18(1):69–76. · doi:10.3233/cbm-160675
- Hanahan D, Weinberg R. Hallmarks of Cancer. Cell. 2000;100:57–70. · DOI · Paper page
- Mierke CT. Physical break-down of the classical view on cancer cell invasion and metastasis. Eur J Cell Biol. 2013;92(3):89–104. · DOI
- Li GN, Livi LL, Gourd CM, Deweerd ES, Hoffman-Kim D. Genomic and morphological changes of neuroblastoma cells in response to three-dimensional matrices. Tissue Eng. 2007;13(5):1035–47. · DOI
- Tadeo I, Piqueras M, Montaner D, et al. Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma. Pediatr Res. 2014;75(2):302–14. · DOI
- Tadeo I, Berbegall AP, Navarro S, Castel V, Noguera R. A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumours. Pediatr Blood Cancer. 2017;64(9). https://doi.org/10.1002/pbc.26449 . · DOI
- Tadeo I, Berbegall AP, Escudero LM, Álvaro T, Noguera R. Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy. Front Oncol. 2014;4:39. · DOI
- Tadeo I, Bueno G, Berbegall AP, et al. Vascular patterns provide therapeutic targets in aggressive neuroblastic tumours. Oncotarget. 2016;7(15):19935–47. · DOI
- Samardzija C, Greening DW, Escalona R, et al. Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling. Sci Rep. 2017;7:46312. · DOI
- Shimada H, Ambros IM, Dehner LP, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86(2):364–72. · DOI · Paper page
- Yin X, Zhang BH, Zheng SS, et al. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/snail signaling. J Hematol Oncol. 2015;8(1):23. · DOI · Paper page
- Chang CC, Shieh GS, Wu P, Lin CC, Shiau AL, Wu CL. Oct-3/4 expression reflects tumour progression and regulates motility of bladder cancer cells. Cancer Res. 2008;68(15):6281–91. · doi:10.1158/0008-5472.can-08-0094
- Dai X, Ge J, Wang X, Qian X, Zhang C, Li X. OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncology Rep. 2013;29(1):155–60. · DOI
- Lin J, Zhang L, Huang H, et al. MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4. Oncotarget. 2015;6(27):23793. · DOI
- Lin H, Sun LH, Han W, et al. Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway. Mol Med Reps. 2014;10(3):1335–42. · doi:10.3892/mmr.2014.2367
- Liu X, Ma M, Duan X, Zhang H, Yang M. Knockdown of OCT4 may sensitize NSCLC cells to cisplatin. Clin Transl Oncol. 2017;19(5):587–92. · doi:10.1007/s12094-016-1569-y
Cited by
Oral squamous cell carcinomas: state of the field and emerging directions
Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 831
Recent advances in mass spectrometry based clinical proteomics: applications to cancer research
Macklin, A., Khan, S., & Kislinger, T. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09283-w · Cited by 317
Mutational drivers of cancer cell migration and invasion
Novikov, N. M., Zolotaryova, S. Y., Gautreau, A. M., & Denisov, E. V. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01149-0 · Cited by 302
Extracellular vesicles: mediators of intercellular communication in tissue injury and disease
Berumen Sánchez, G., Bunn, K. E., Pua, H. H., & Rafat, M. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00787-y · Cited by 289
Luo, X., Gong, H.-B., Gao, H.-Y., Wu, Y.-P., Sun, W.-Y., Li, Z.-Q., Wang, G., Liu, B., Liang, L., Kurihara, H., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00719-2 · Cited by 261
Metadata
- Authors
- Monferrer, E., Burgos-Panadero, R., Blanquer-Maceiras, M., Cañete, A., Navarro, S., & Noguera, R.
- Venue
- BMC Cancer
- Published
- 2019-01-03
- Volume
- 19
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2947601703
- Cited by
- 196
- References
- 2
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- European Regional Development Fund (PI14/01008, PI17/01558)
- CIBERONC (CB16/12/00484)
- Fundación Científica Asociación Española Contra el Cáncer (FAECC2015/2016)
- NEN Association
- Neuroblastoma Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High Oct4 expression: implications in the pathogenesis of neuroblastic tumours. https://app.cochat.ai/papers/10.1186/s12885-018-5219-3
- The paper
- Monferrer, E., Burgos-Panadero, R., Blanquer-Maceiras, M., Cañete, A., Navarro, S., & Noguera, R. (2019). High Oct4 expression: implications in the pathogenesis of neuroblastic tumours. BMC Cancer. https://doi.org/10.1186/s12885-018-5219-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.